Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

CAR-T, bispecifics or ADCs in late-stage RRMM

Treatment of multiple myeloma in Turkey

Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour hot in prostate cancer

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC

EAU 2024: Bladder cancer latest

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status